Challenge Study Shows Efficacy of RSV Vaccine in Healthy Adults
For healthy adults, the bivalent prefusion F respiratory syncytial virus vaccine is effective against symptomatic RSV infection and viral shedding.
For healthy adults, the bivalent prefusion F respiratory syncytial virus vaccine is effective against symptomatic RSV infection and viral shedding.
In this interview, Paritosh Prasad, MD, provides insight into the recent outbreak of monkeypox.
Patients in the first arm will undergo single booster vaccination, and patients in the second arm will undergo full revaccination.
Types of COVID-19 vaccines in the US, including those approved by the FDA under Emergency Use Authorization, as well as other investigational products currently in Phase 3 clinical trials.
As the medical field shifted its priorities to treating COVID-19 at the start of the pandemic, routine immunization was one of the many medical fields to experience disruption. What was the scope of this disruption and what are possible ways to address it?
The designation was based on data from a phase 1/2 study that evaluated a single intramuscular injection of V116 in pneumococcal-naïve adults.
How effective is the 13-valent pneumococcal conjugate vaccine in preventing pneumonia and lower respiratory tract infection hospitalizations in older adults?
For children aged 5 to 17 years with asthma, quadrivalent live attenuated influenza vaccine is noninferior to quadrivalent IIV4 for frequency of asthma exacerbations.
The RSVpreF vaccine candidate consists of 2 prefusion F proteins selected to optimize protection against RSV A and B.
The Emergency Use Authorization was based on safety and immunogenicity data provided to the Agency.